Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

1.

Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia.

Matza LS, Phillips GA, Revicki DA, Ascher-Svanum H, Malley KG, Palsgrove AC, Faries DE, Stauffer V, Kinon BJ, George Awad A, Keefe RS, Naber D.

Psychiatry Res. 2012 Dec 30;200(2-3):835-42. doi: 10.1016/j.psychres.2012.05.005. Epub 2012 Jul 28.

PMID:
22841345
[PubMed - indexed for MEDLINE]
2.

Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation.

Matza LS, Phillips GA, Revicki DA, Ascher-Svanum H, Malley KG, Palsgrove AC, Faries DE, Stauffer V, Kinon BJ, Awad AG, Keefe RS, Naber D.

Patient Prefer Adherence. 2012;6:521-32. doi: 10.2147/PPA.S25635. Epub 2012 Jul 13.

PMID:
22879738
[PubMed]
Free PMC Article
3.

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial.

Faries D, Ascher-Svanum H, Phillips G, Nyhuis AW, Sugihara T, Stauffer V, Kinon BJ.

BMC Med Res Methodol. 2012 Sep 13;12:142. doi: 10.1186/1471-2288-12-142.

PMID:
22974273
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Development of a clinician questionnaire and patient interview to assess reasons for antipsychotic discontinuation.

Matza LS, Phillips GA, Revicki DA, Ascher-Svanum H, Kaiser D, Stauffer V, Shorr JM, Kinon BJ.

Psychiatry Res. 2011 Oct 30;189(3):463-8. doi: 10.1016/j.psychres.2011.05.030. Epub 2011 Jun 17.

PMID:
21684017
[PubMed - indexed for MEDLINE]
5.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

PMID:
16707074
[PubMed - indexed for MEDLINE]
Free Article
6.

Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients.

Vernon MK, Revicki DA, Awad AG, Dirani R, Panish J, Canuso CM, Grinspan A, Mannix S, Kalali AH.

Schizophr Res. 2010 May;118(1-3):271-8. doi: 10.1016/j.schres.2010.01.021. Epub 2010 Feb 20.

PMID:
20172695
[PubMed - indexed for MEDLINE]
7.

Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives.

Ascher-Svanum H, Nyhuis AW, Stauffer V, Kinon BJ, Faries DE, Phillips GA, Schuh K, Awad AG, Keefe R, Naber D.

Curr Med Res Opin. 2010 Oct;26(10):2403-10. doi: 10.1185/03007995.2010.515900.

PMID:
20812791
[PubMed - indexed for MEDLINE]
8.

Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder.

Dunayevich E, Ascher-Svanum H, Zhao F, Jacobson JG, Phillips GA, Dellva MA, Green AI.

J Clin Psychiatry. 2007 Aug;68(8):1163-71.

PMID:
17854239
[PubMed - indexed for MEDLINE]
9.

Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder.

Tandon R, Devellis RF, Han J, Li H, Frangou S, Dursun S, Beuzen JN, Carson W, Corey-Lisle PK, Falissard B, Jody DN, Kujawa MJ, L'italien G, Marcus RN, McQuade RD, Ray S, Van Peborgh P; IAQ Validation Study Group.

Psychiatry Res. 2005 Sep 15;136(2-3):211-21.

PMID:
16115690
[PubMed - indexed for MEDLINE]
10.

The Patient Assessment Questionnaire: initial validation of a measure of treatment effectiveness for patients with schizophrenia and schizoaffective disorder.

Mojtabai R, Corey-Lisle PK, Ip EH, Kopeykina I, Haeri S, Cohen LJ, Shumaker S.

Psychiatry Res. 2012 Dec 30;200(2-3):857-66. doi: 10.1016/j.psychres.2012.06.006. Epub 2012 Jul 26.

PMID:
22840524
[PubMed - indexed for MEDLINE]
11.

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians.

Chen J, Ascher-Svanum H, Nyhuis AW, Case MG, Phillips GA, Schuh KJ, Hoffmann VP.

Patient Prefer Adherence. 2011;5:547-54. doi: 10.2147/PPA.S23255. Epub 2011 Nov 3.

PMID:
22114469
[PubMed]
Free PMC Article
12.

Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia.

Patrick DL, Burns T, Morosini P, Rothman M, Gagnon DD, Wild D, Adriaenssen I.

Curr Med Res Opin. 2009 Feb;25(2):325-38. doi: 10.1185/03007990802611919 .

PMID:
19192977
[PubMed - indexed for MEDLINE]
13.

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW.

Arch Gen Psychiatry. 2006 Oct;63(10):1079-87.

PMID:
17015810
[PubMed - indexed for MEDLINE]
14.

Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.

Rosa F, Schreiner A, Thomas P, Sherif T.

Clin Drug Investig. 2012 Apr 1;32(4):267-79. doi: 10.2165/11599080-000000000-00000.

PMID:
22339430
[PubMed - indexed for MEDLINE]
15.

Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.

Ganguli R, Brar JS, Mahmoud R, Berry SA, Pandina GJ.

BMC Med. 2008 Jun 30;6:17. doi: 10.1186/1741-7015-6-17.

PMID:
18590519
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Factors related to different reasons for antipsychotic drug discontinuation in the treatment of schizophrenia: a naturalistic 18-month follow-up study.

Vita A, Barlati S, Deste G, Corsini P, De Peri L, Sacchetti E.

Psychiatry Res. 2012 Dec 30;200(2-3):96-101. doi: 10.1016/j.psychres.2012.07.006. Epub 2012 Aug 1.

PMID:
22858250
[PubMed - indexed for MEDLINE]
17.

Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.

Ratner Y, Gibel A, Yorkov V, Ritsner MS.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Oct 1;31(7):1401-9. Epub 2007 Jun 21.

PMID:
17669574
[PubMed - indexed for MEDLINE]
18.

[Relationships between insight and medication adherence in subjects with psychosis].

Droulout T, Liraud F, Verdoux H.

Encephale. 2003 Sep-Oct;29(5):430-7. French.

PMID:
14615692
[PubMed - indexed for MEDLINE]
19.

Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales.

Wolters HA, Knegtering H, van den Bosch RJ, Wiersma D.

Schizophr Res. 2009 Jul;112(1-3):114-8. doi: 10.1016/j.schres.2009.03.026. Epub 2009 Apr 23.

PMID:
19395241
[PubMed - indexed for MEDLINE]
20.

Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia.

Wehmeier PM, Kluge M, Schacht A, Helsberg K, Schreiber W, Schimmelmann BG, Lambert M.

J Psychiatr Res. 2008 Jul;42(8):676-83. Epub 2007 Aug 27.

PMID:
17720192
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk